My new pinned tweet, #NWBO. #future

Further manufacturing expansion will be needed.

Despite the grade C suite buildout with flaskworks, my worry is that NWBO still will not be able to meet demand, even with UK approval, let alone future approvals in US, Europe, Canada, etc. There will be a demand problem.

The hurdle that is as immense as the product itself is the manufacturing. Cutting cost of production is needed to increase margins. Which allows for higher valuation. The moat of manufacturing also adds value. All of this is on top of the low side effect DCVax. #NWBO

NWBO paid $8-10 million for Advent when fair market value would have been $60-120 million. NWBO has an enterprise value of $411 million. There is hidden value in the ownership of Advent alone. Artificially suppressed by shorts. Love me a good deal.

Market has not realized the dendritic cell vaccine optimization moat but also the manufacturing moat #NWBO #Flaskworks #DCVax

I have been emphasizing manufacturing for years, now NWBO owns its own manufacturing. How about them apples?

Added to the collection today, thankfully in the last 2 minutes of trading at a great price. #NWBO

Does anyone know why GE cardiolab auto updates an additional time when doing an atrial extra-stim. It does not allow for easy measurements of HV on the review screen. Does any #epeeps @EPeeps_Bot have an answer to this problem?

📊NWBO's DCVax-L Long Term Survival Data $NWBO A quick summary of the unprecedented DCVax-L survival data. ✅DCVax-L in nGBM 25/232 alive at 5 years versus 0/1366 contemporaneous external controls See Image 1. ✅DCVax-L in rGBM 2/64 alive at 5 years versus 0/640

💯 agree about planning for acquisition by a larger company. Particularly after MHRA approval. It also allows the buyer to know that manufacturing is already set up and owned by NWBO.

Efficiency and being able to dramatically increase production volumes of DCVax is essential. It won’t be a demand problem, but a supply problem if they can’t mass produce personalized vaccine.

Per #NWBO last sec filing - further news on manufacturing. I have been saying it for a long time now, manufacturing is key.

Karma is a bitch #NWBO

The humanitarian crisis in Gaza is unimaginably acute and devastatingly heartbreaking. Children and families are starving, and the entire population faces severe deprivation and unimaginable suffering. The evidence is overwhelming, with multiple aid agencies and countries

If you are read up on NWBO, Flaskworks, you will realize the significant potential and what NWBO is aiming for, it’s much more than DCVax, it’s not a central production facility. Future is personalized medicine manufactured on site. I have been saying - focus on manufacturing

#NWBO followers certainly do their due diligence, all of this is verifiable. My money has been on dendritic cell therapy because I believe the human evolution of dendritic cells has evolved to be better than other current solutions, simple as that.

$NWBO I have looked into the due diligence of @andrewcaravello and @d_stock07734 This is a ping-pong deep research piece on Mayo, Mill Creek, Merck and NWBO. Thanks to Andrew and Dstock 🙏🏻 https://t.co/H50MVQ8lzY

Think of it this way, Powers has been focused on patents and manufacturing, now she made her bets on multiple cancer types. You don’t do this type of thing unless you are very confident of regulatory approval. Also she is always thinking multiple steps ahead. Impressive.

This reflects a strategic vision of building a comprehensive dendritic cell franchise that can address multiple cancer types and treatment approaches.

#NWBO #Roswell As CEO Linda Powers stated, while the company continues to “focus intensively on pursuing the approval and commercialization of DCVax-L for glioblastoma”, they are “excited to begin working on growth opportunities with the licensed technologies”.